NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

$33.87

-0.66 (-1.91%)

(As of 09/25/2023 ET)

Compare

Today's Range: $33.59
▼
$34.64
50-Day Range: $29.80
▼
$37.76
52-Week Range: $23.89
▼
$47.25

Volume: 369,031 shs
Average Volume: 507,798 shs
Market Capitalization: $1.99 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $57.88

Ventyx Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 70.9% Upside
$57.88 Price Target
Short Interest: Bearish
20.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.38
Based on 5 Articles This Week
Insider Trading: Selling Shares
$17.78 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.26) to ($3.85) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

741st out of 961 stocks

Pharmaceutical Preparations Industry

345th out of 454 stocks

3.5

Analyst's Opinion

Consensus Rating
Ventyx Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $57.88, Ventyx Biosciences has a forecasted upside of 70.9% from its current price of $33.87.
Amount of Analyst Coverage
Ventyx Biosciences has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
20.71% of the float of Ventyx Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Ventyx Biosciences has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Ventyx Biosciences has recently decreased by 1.50%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Ventyx Biosciences does not currently pay a dividend.
Dividend Growth
Ventyx Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTYX.

2.4

News and Social Media Coverage

News Sentiment
Ventyx Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Ventyx Biosciences this week, compared to 2 articles on an average week.
MarketBeat Follows
4 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ventyx Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,778,968.00 in company stock.
Percentage Held by Insiders
24.39% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Ventyx Biosciences are expected to decrease in the coming year, from ($3.26) to ($3.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ventyx Biosciences is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ventyx Biosciences is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ventyx Biosciences has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

VTYX Price History

30 days | 90 days | 365 days | Advanced Chart

VTYX Stock News Headlines

September 24, 2023 | americanbankingnews.com

Ventyx Biosciences (NASDAQ:VTYX) Stock Price Down 2.5%

September 24, 2023 | americanbankingnews.com

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of "Buy" from Analysts

September 26, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 22, 2023 | americanbankingnews.com

Somu Subramaniam Sells 56,665 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

September 11, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)

September 11, 2023 | finance.yahoo.com

Insider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences Inc

August 20, 2023 | fool.com

Ventyx Biosciences (NASDAQ: VTYX)

August 15, 2023 | finance.yahoo.com

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript

September 26, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

August 14, 2023 | seekingalpha.com

Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Amylyx Pharmaceuticals Inc (AMLX) and Aptose Biosciences (APTO)

August 11, 2023 | markets.businessinsider.com

Where Ventyx Biosciences Stands With Analysts

August 11, 2023 | finanznachrichten.de

Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress

August 11, 2023 | finance.yahoo.com

Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress

August 3, 2023 | finance.yahoo.com

Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023

August 2, 2023 | finance.yahoo.com

Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference

July 11, 2023 | markets.businessinsider.com

Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

July 7, 2023 | seekingalpha.com

Why did Ventyx Biosciences stock drop today? Large shareholder sale

July 7, 2023 | benzinga.com

Director of Ventyx Biosciences Makes $5.23M Sale

July 7, 2023 | benzinga.com

10% Owner of Ventyx Biosciences Sold $5.23M In Stock

July 6, 2023 | benzinga.com

Chief Executive Officer at Ventyx Biosciences Exercises Options Worth $1.08M

July 6, 2023 | benzinga.com

Chief Business Officer at Ventyx Biosciences Exercises Options Worth $546K

July 5, 2023 | markets.businessinsider.com

Analyst Ratings for Ventyx Biosciences

July 5, 2023 | markets.businessinsider.com

LifeSci Capital Remains a Buy on Ventyx Biosciences (VTYX)

July 5, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Ventyx Biosciences (VTYX), Avadel Pharmaceuticals (AVDL)

July 3, 2023 | finance.yahoo.com

Why Shares of Ventyx Biosciences Rose Monday

June 15, 2023 | seekingalpha.com

Ventyx: Critical Proof Of Concept Data Later This Year

See More Headlines

Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Company Calendar

Last Earnings: 8/10/2023
Today: 9/26/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VTYX
CUSIP: N/A
CIK: 1851194
Web: www.ventyxbio.com
Phone: 760-593-4832
Fax: N/A
Employees: 91
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $57.88
High Stock Price Forecast: $77.00
Low Stock Price Forecast: $46.00
Forecasted Upside/Downside: +70.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -43.67%
Return on Assets: -41.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.31
Quick Ratio: 17.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.25 per share
Price / Book: 5.42

Miscellaneous

Outstanding Shares: 58,710,000
Free Float: 44,391,000
Market Cap: $1.99 billion
Optionable: Not Optionable
Beta: -0.36

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Sheila K. Gujrathi M.D. (Age 53)
Exec. Chairperson
Comp: $125k

Dr. Raju S. Mohan Ph.D. (Age 65)
Founder, CEO & Director
Comp: $989.99k

Dr. William J. Sandborn M.D. (Age 60)
Ph.D., Pres & Chief Medical Officer
Comp: $872.26k

Dr. John M. Nuss Ph.D. (Age 64)
Chief Scientific Officer
Comp: $656.99k

Dr. Martin Douglas Auster M.D. (Age 48)
Chief Financial Officer

Mr. Christopher W. Krueger J.D. (Age 55)
MBA, Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VTYX Stock - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTYX shares.
View VTYX analyst ratings or view top-rated stocks.
What is Ventyx Biosciences' stock price forecast for 2023?: 7 analysts have issued 1-year price objectives for Ventyx Biosciences' shares. Their VTYX share price forecasts range from $46.00 to $77.00. On average, they expect the company's share price to reach $57.88 in the next twelve months. This suggests a possible upside of 70.9% from the stock's current price.
View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts.
How have VTYX shares performed in 2023?: Ventyx Biosciences' stock was trading at $32.79 at the beginning of the year. Since then, VTYX shares have increased by 3.3% and is now trading at $33.87.
View the best growth stocks for 2023 here.
When is Ventyx Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our VTYX earnings forecast.
How were Ventyx Biosciences' earnings last quarter?: Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its earnings results on Thursday, August, 10th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.20. During the same quarter in the prior year, the company posted ($0.39) earnings per share.
What ETFs hold Ventyx Biosciences' stock?: ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), Alger Mid Cap 40 ETF (FRTY), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares U.S. Pharmaceuticals ETF (IHE).

When did Ventyx Biosciences IPO?: (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.
What is Ventyx Biosciences' stock symbol?: Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."
Who are Ventyx Biosciences' major shareholders?: Ventyx Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.99%), Capital International Investors (5.07%), Goldman Sachs Group Inc. (2.66%), Holocene Advisors LP (2.61%), State Street Corp (1.77%) and Driehaus Capital Management LLC (1.64%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends.
How do I buy shares of Ventyx Biosciences?: Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ventyx Biosciences' stock price today?: One share of VTYX stock can currently be purchased for approximately $33.87.
How much money does Ventyx Biosciences make?: Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $1.99 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.
How can I contact Ventyx Biosciences?: The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com.

This page (NASDAQ:VTYX) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

Ventyx Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ventyx Biosciences (NASDAQ:VTYX) Stock

VTYX Price History

VTYX Stock News Headlines

VTYX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VTYX Stock - Frequently Asked Questions

Overall MarketRank^™